Pregabalin litigation - why did the SPCs lapse?

No items found.
31 May 2018
Tags
Life

Writing in the GRUR Newsletter ahead of the decision of the Supreme Court on the validity of a European patent owned by a subsidiary of Pfizer, covering the use of pregabalin in the treatment of pain, Darren Smyth looks at the various theories as to why the related SPCs were allowed to lapse.

Related articles

EIP welcomes Anders Hansson as Partner to further strengthen our digital practice
19 January 2026
EIP is pleased to welcome Anders Hansson as Partner, bringing nearly 20 years of experience in AI, robotics, digital technologies, and European patent strategy. His industry and private‑practice background further strengthens our digital and high‑tech capabilities across Europe.
EIP Launches Tech & AI Function to Drive Innovation and Client Excellence
06 November 2025
When it comes to technology, EIP has always been ahead of the curve; we are proud to announce the evolution of our IT department into a dedicated Tech & AI function, marking a bold step towards...
Trade Secrets: Navigating geopolitical risks and IP theft in the semiconductor industry
04 November 2025
Semiconductors have always been a critical technology but have grown significantly in strategic importance in recent years. They have become the key building block in developing and existing markets, including quantum computing, edge computing, AI, IoT, automotive, cellular data technology, smartphones, robotics, and many more. The complex designs and innovations that power semiconductor manufacturing are invaluable both to the world’s economy and technological advancement. Consequently, the semiconductor industry has found itself at the centre of geopolitical tensions, especially between the United States and China. It has become a prime target for cyberattacks and intellectual-property (IP) theft. As such, companies operating in this area must be more vigilant in protecting their intellectual assets.